INTRODUCTIONCholangiocarcinoma accounts for 3% of gastrointestinal malignancies worldwide, with 3500 cases diagnosed per year in the United States, the majority of which (60‐80%) arise in the perihilar region. Unresectable disease has a dismal prognosis, with a median survival of less than 1 year. Margin negative R0 resection provides the only chance for long‐term cure. Despite this, resectable disease has a 5‐year survival between 20% and 50%. Adjuvant therapy (AT) has been advocated after resected hilar cholangiocarcinoma (HC) to improve outcomes.The role of AT for resected HC is a source of significant debate. Current National Comprehensive Cancer Network (NCCN) guidelines for AT in resected HC comment that more data are necessary in order to make firm conclusions. In two recent retrospective reviews of AT in biliary tract cancer (BTC), no survival benefit was found. Conversely, within the last 10 years three single center retrospective studies have demonstrated a survival benefit with AT in resected extrahepatic cholangiocarcinoma. In the only published phase III randomized trial of AT that included patients with HC, and in the recently completed phase III trial of gemcitabine plus oxaliplatin in BTC, there was no significant survival benefit noted.Herein, we sought to determine the role of AT
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera